We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly said its combination antibody therapy, bamlanivimab and etesevimab, reduced the risk of hospitalization and death by 87 percent in a late-stage study of 769 high-risk COVID-19 patients — and worked against emerging variant strains of the coronavirus. Read More
The Pfizer/BioNTech COVID-19 vaccine demonstrated effectiveness against a Brazilian coronavirus strain that has quickly spread throughout the country, a study has found. Read More
Researchers found that plasma samples had six times less neutralizing capacity against the Brazilian strain than against the UK and South African strains. Read More
“While we are disappointed that BRII-196 and BRII-198 have not shown clear benefits during the interim analysis … we remain committed to investigating this antibody combination in ambulatory COVID-19 patients through the ongoing ACTIV-2 trial,” said Brii Biosciences CEO Zhi Hong. Read More
Gilead Sciences’ daily oral HIV blockbuster Biktarvy has shown success as a long-term treatment, demonstrating continued high efficacy and strong viral suppression in two phase 3 trials that conducted years of follow-up. Read More
Pfizer and French drugmaker Valneva have initiated a new phase 2 study evaluating VLA15, their experimental vaccine for Lyme disease — and say this is likely to be the last one before the candidate progresses to phase 3 trials. Read More
Merck and Ridgeback Biotherapeutics have said their experimental COVID-19 antiviral MK-4482 (molnupiravir) significantly reduced infection after five days of treatment in a clinical trial. Read More
According to Lilly, tirzepatide reduced blood sugar levels by 2.09 percent at 5 mg, 2.37 percent at 10 mg and 2.46 percent at 15 mg, vs. 1.86 percent for 1 mg of Ozempic. Read More
The UK’s RECOVERY trial, which is assessing multiple potential COVID-19 treatments, has stopped enrollment in its arm evaluating colchicine, an anti-inflammatory drug used to treat gout. Read More
Merck’s anti-parasitic drug Stromectol (ivermectin) did not help speed recovery in patients with mild COVID-19, researchers in Cali, Colombia, found in a small clinical trial. Read More
“While we are disappointed with the recommendation … We are encouraged by the safety profile of VIR-7831 and by the possibility of a benefit on top of remdesivir and corticosteroids in this advanced cohort of patients,” said Vir Biotechnology CEO George Scangos. Read More
Worldwide trials of the shot have shown wide variations in efficacy rates, and the company has faced criticism for a lack of transparency regarding its trial findings. Read More